Oslo, Norway, 29 October 2025 - Photocure ASA (OSE:PHO) today reported
Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3
2024: NOK 120.1 million), and an EBITDA of NOK 10.2 million (Q3 2024: NOK 5.0
million) for the company. Looking ahead, Photocure expects product revenue
growth in the range of 8% to 10% on a constant currency basis (compared to 7 to
11% previously) and an EBITDA improvement in 2025. While the company is not
providing a specific EBITDA guidance range, Photocure expects continued
operating leverage flow-through in its core commercial business and significant
potential growth in milestones this year.
"Photocure delivered another strong quarter, extending our track record of
double-digit topline revenue growth with positive EBITDA. We continued to
execute with discipline this quarter while in parallel advancing new growth
initiatives that further amplify our central role in precision diagnostics for
bladder cancer," said Dan Schneider, President & Chief Executive Officer of
Photocure.
The company continued to execute on its plan to expand blue light cystoscopy
(BLC®) use in Q3 2025 with the installation of 14 new Saphira towers in the U.S.
- 7 new accounts and 7 blue light tower upgrades. In addition, due to increasing
demand, ForTec has acquired and deployed 6 additional BLC towers, bringing the
total number of mobile BLC towers to 24. With the increasing momentum provided
by ForTec's mobile solution, Photocure had 373 active accounts in the U.S. at
the end of the quarter, an increase of 23% versus the second quarter of 2024.
Across Europe, a total of 49 Olympus Visera Elite III blue light cystoscopy
(BLC) capable systems were installed since the launch in Q1 2025.
Total revenues ended at NOK 135.0 million in the third quarter of 2025, up from
NOK 120.2 million, with an EBIT of NOK 2.9 million (-2.2). Cash and cash
equivalents were NOK 247.8 million at the end of the period.
After the closing of the quarter, Photocure announced a partnership with
Intelligent Scopes Corporation (ISC), a U.S. subsidiary of Claritas HealthTech,
to develop AI software to support physicians in real-time during BLC, improving
early-stage bladder cancer detection, diagnosis and resection completeness.
"Together, Photocure and ISC intend to pursue FDA clearance for the AI software
compatible with any BLC system. Based on the terms of the agreement, Photocure
will have exclusive, perpetual rights to commercialize the new solution via its
direct sales force, distributors or partners, as well as license the software to
device manufacturers in any given country upon regulatory clearance. Our
partnership with ISC, along with other strategic initiatives underway,
represents a step toward expanding clinical adoption, driving operating
leverage, and building long-term intrinsic value for shareholders," Schneider
added.
Photocure believes that the benefits of BLC with Hexvix/Cysview offer superior
detection and management of bladder cancer..
"Looking ahead, we anticipate sustained revenue growth, fueled by rigid kit
adoption, expansion of mobile BLC, and HD upgrades that enhance utilization and
sales. The tailwinds from a wave of recently approved NMIBC therapeutics are
raising awareness around early detection and personalized disease management,
validating Photocure's position at the center of this rapidly evolving
ecosystem. In addition to our commercial progress, we are encouraged by
potential catalysts that could further strengthen our growth trajectory. These
include CMS reimbursement developments, reintroduction of flexible BLC solutions
to the market, entrance of additional equipment manufacturers and a potential
FDA reclassification in favor of BLC from a citizen's petition - each
representing an opportunity to broaden patient access and accelerate adoption.
Lastly, our license agreement with Asieris for Cevira has potential to trigger a
significant milestone payment when it receives regulatory approval in China,"
Schneider concluded.
Please find the full financial report and presentation enclosed.
EBITDA* and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
third quarter 2025 financial report on page 25.
The quarterly report and presentation will be published at 07:00 CEST and will
be publicly available at www.photocure.com. Dan Schneider, CEO and Erik Dahl,
CFO, will host a live webcast at 14:00 CEST.
The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through:
https://channel.royalcast.com/landingpage/hegnarmedia/20251029_2/
The presentation is scheduled to conclude at 14:45 CEST.
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no
Priyam Shah
Vice President Investor Relations
Tel: +1 7176815072
Email: priyam.shah@photocure.com
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no (geir.bjorlo@corpcom.no
)
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com/news
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Photocure ASA, on 29 October 2025
at 07:00 CEST.